These 3 biotechs could bring you gains of 422% in just 6 months
Today's Financial News - Posted March 23, 2009
The next generation in revolutionary biotechs has arrived. (And they may be the only way to make money in this market!)
Each one of these 3 breakout stocks could realistically bring you gains of 128%, 185%, or even 422% in the next 6 months!
Jan. 23, 2009 was a historic date in the history of U.S. medicine: The FDA, for the first time ever, gave a company approval to begin clinical trials of a therapy based on human embryonic stem cell technology.
The lucky recipient was Geron Corporation.
On Jan. 23, when the biotech announced it had received clearance for testing of it’s GRNOPC1 for patients with acute spinal cord injury, the stock jumped over 61% from its closing price the day before!
I had recommended readers invest in the biotech just 9 days prior, on Jan. 12.
If you’d taken my advice to snatch up that stock, you could have cashed out for gains of over 75% in just 13 trading days!
And prior to that recommendation of Geron, I had recommended the stock twice before back in 2008. Readers who bought shares saw gains of 20% or more each time!
I KNEW that company was golden—its revolutionary proprietary technology set it above the rest.
If only a single one of its therapies complete its rigorous clinical trials successfully, the stock could realistically see gains of 128%… 185%… even 422%… within 6 months.
That’s the kind of potential I see for 3 tiny biotechs I’ve just uncovered.
And what they are trying to achieve is no less than…
The holy grail of medicine
Live long enough and there’s a pretty good chance that you’ll develop cancer. All that’s left to wonder is what form the disease may take.
Just look at the numbers: Last year in the U.S. alone…
- Roughly 66,120 cases of Non-Hodgkin Lymphoma were diagnosed
- About 148,810 people were told they have Colon or Rectal Cancer
- Approximately 215,020 tests came back positive for Lung Cancer
- And more than 1 million cases of Skin Cancer were first reported.
A cure for cancer. It’s the ultimate dream… the holy grail of medicine…
… and of investors who’ve bought shares in the companies with research and products that blaze the trail.
In my Special Report, 3 Biotechs That Could Revolutionize Medicine (and make you RICH!), I’ll let you in on 3 small companies that are tackling these and other forms of cancers… each in their own unique, groundbreaking way.
Let me tell you about the first stock I found. We’ll call it “Company A”.
But first, just a word of warning…
I’m going to get a little technical. I want you to see the potential of this biotech’s research (and the enormous upside it could bring to their stock prices), so bear with me…
Company A: Supercharging the immune system
Our body’s immune system defends us from infectious disease and foreign matter.
Lymphocytes, a type of white blood cell, are agents of the immune system.
Two key types of lymphocytes derived from stem cells in the bone marrow are B cells and T cells.
B cells remain in the bone marrow. As long as a foreign antigen is present, they can produce antibodies.
T cells finish their development in the thymus. A major subtype is the Cytotoxic (“killer”) T cell. They attack cells that carry foreign or abnormal antigens on their surface
Imagine it as a kind of Rottweiler trained to recognize antigens with specific molecules.
Company A uses a proprietary technology that instructs cytotoxic T cells to inject deadly proteins into tumor cells.
This induces cell death.
Let’s be clear about this, because it’s pretty amazing stuff…
Company A’s treatment actually “teaches” our body’s own killer T cells to attack and kill cancerous cells.
Even more remarkable: That targeted “killer” knowledge then remains in our T cells.
Let me explain…
Instructional therapy
This treatment “teaches” the immune system to fight the specific cancerous cells it’s targeting—forever.
It’s called “active immunity”.
The company already has drugs in Phase I and II clinical trials to treat different types of cancer.
And its technology is being applied to a variety of other diseases.
Company A is on target to bring an entirely new approach to cancer treatment and right now, it’s stock is trading for under $4!
One breakthrough… one news release touting success… could send this stock to the moon! And give early investors potential gains of 422%!
But this isn’t the only emerging company using new weapons in the battle against cancer…
Company B: A molecular approach
Again, a little science…
Within a cell, molecules signal each other to activate and perform a function.
One such a function could be cell division. Another could be cell death.
Research indicates that improper activation could lead to some forms of cancer.
Company B’s scientists have developed a revolutionary approach that involves generating molecules to tackle any abnormally regulated signaling pathways.
That’s quite a mouthful, I know. But it’s the reason an industry leader like Genentech was eager to partner with them for two of its treatments.
Company B’s top therapeutic candidate is currently in clinical trials for metastatic basal cell carcinoma and metastatic colorectal cancer.
Additional trial applications will begin later this year.
Chances of success are excellent. (Why else would Genentech be on board?)
Shockingly, this company’s shares are still trading for under $2!
And as the clinical trials progress, that low share price could easily skyrocket up by 422%—it’s happened before.
You can read all about it in my Special Report, 3 Biotechs That Could Revolutionize Medicine (and make you RICH!).
My third biotech pick has me even more excited… but more on that in a minute.
First…
Let’s talk stem cells
The new political climate in the U.S. has greatly increased interest in biotechs—especially those focused on stem cell therapies.
And with the FDA’s approval for the testing of Geron’s GRNOPC1, the potential for truly astounding breakthroughs in medicine has entered the public’s imagination.
A human embryonic stem cell (hESC), as compared to an adult stem cell, has greater flexibility both for treatments and for lab testing.
Adult stem cells, as a general rule, can only be relied on to divide and replicate into cell types of their original tissue.
But hESCs can develop into any and all cell types.
An added benefit is that hESCs are much easier to grow in culture than the adult variety.
Federal funding will allow small biotechs in the U.S. to compete with international pharma companies already delving into the potential of hESCs.
And it’s believed that very soon most therapies will be “customized”—specifically designed to maximize effectiveness by working with a patient’s individual genetic makeup.
NOW is the time to get in on these companies. The upside potential here is HUGE.
Ahead of the mainstream
Under the leadership of our executive publisher, J. Christoph Amberger, the TFN team is constantly searching the markets for the next big trend.
We make our research available on the TodaysFinancialNews.com website and in our free TFN eNews daily email.
But what we’re really looking for are the once-in-a-lifetime golden profit opportunities for Members of our premium investment research service, Hot Stock Confidential.
They’re companies whose insiders are buying… that have easy-to-understand business concepts, established markets, growing revenues and unique products.
Some, like those in my new Special Report, are making great progress in the fields of biotechnology… genetics… medical diagnostics. Long-term, they should prove excellent investments.
But in the meantime, every small breakthrough… every successful step in the approval process… holds the potential for amazing short-term profits. Especially in volatile markets like these!
In many instances the daily trading volume of these companies is so light, a single story in the mainstream media… an Internet rumor… a line dropped on a bulletin board… could double or triple their average daily trading activity and push stock prices out of our advisable buying range.
Early last summer, we felt the tremors of an economic collapse on the way.
Healthcare is one of the most recession-resistant sectors out there.
And sure enough, medical, biotech and pharma stocks proved to be great defensive plays, but more importantly, some of the top gainers in the market.
And Hot Stock Confidential Members who followed our recommendations reaped the benefits…
- 41.8% on Nimox Pharmaceuticals (NYMX) in 21 trading days…
- 22.7% on Emergent Biosolutions (EBS) in 29 trading days…
- 20.3% on Osiris Therapeutics Inc. (OSIR) in 19 trading days…
- 23.7% on Geron Corporation (GERN) in 16 trading days…
- 35% on Vanda Pharmaceuticals Inc. (VNDA) in 37 trading days…
- 26.7% on Synta Pharmaceuticals (SNTA) in 21 trading days…
- 51.2% on Aastrom Biosciences (ASTM) in 29 trading days…
- 23.2% on Stem Cells Inc. (STEM) in just 6 trading days…
- and 20% on Cerus Corporation (CERS) in 16 trading days.
The oldest pick listed here was from May 2008.
That’s an average gain of 29.4% for those stocks related to medical advances in the past 7 months.
In the same time period, the Dow dropped by 32.2%, the S&P fell by 36.4% and the Nasdaq was down by 4.1%.
But healthcare isn’t the only place we found winners for Hot Stock Confidential Members…
Your Pipeline of Profitable Opportunities
We found our readers gains in energy, retail, financial institutions—even sin stocks. Here’s just a sampling…
- 40.3% on Pyramid Oil Company (PDO) in 9 trading days…
- 34.8% on Alon USA Energy (ALJ) in 31 trading days…
- 71.9% on Under Armour Jan 30 Puts (UAMF) in 5 trading days…
- 79.6% on Boeing Feb 55 Puts (BANK)…
- 35% on Oshkosh Corporation (OSK) in 11 trading days…
- 55% on Rex Energy (REXX) in 31 trading days…
- 87.1% on National City Jan 2.5 Calls (NCCAZ)…
- 44.2% on Bank of America (BAC) in only 1 day…
- 65.9% on CitiGroup (C) in just 2 trading days…
- and 83.2% on Altria 2008 Nov 22 17.00 Calls (MOKR) in a single day.
I’m certain that the 3 stocks in my Report, 3 Biotechs That Could Revolutionize Medicine (and make you RICH!), will bring in even bigger gains!
The other reason I like these 3 stocks?
“Feel good” investments
When you put your money behind a drug development company, you’re helping to fund research that could save lives.
FDA approval of even just one of these companies’ therapies could entirely revolutionize medical treatment going forward.
No less than that.
Now, there’s risk involved…
These top scientists could be barking up the wrong tree…. their technology could become obsolete in months… they could fail clinical trials due to unforeseen complications…
It happens all the time.
But when all goes well, it’s…
A goldmine for investors
Like on May 19, 2003 when Genentech announced the clinical success of its cancer drug, Avastin.
Genetech’s stock price climbed up over 104% less than a month after the press release came out
The share price went up 128% 6 months after the announcement.
Or there’s Idenix Pharmaceuticals…
On Jan. 7, 2008, the company presented the promising preclinical results of the products in their Hepatitis C pipeline at a JP Morgan Healthcare Conference.
Within a month, Idenix’s share price went from $2.63 up to $5.56—a gain of 111.4%!
Less than 6 months later, it was up 185%.
And even more astounding, on Jan. 13, 2006, Generex Biotechnology announced it was beginning trials of its Oral-lyn insulin spray for suffers of Type-1 diabetes.
Generex’s stock went on to rise 422.9% in just over 2 months!
You see, these kinds of gains are quite simply, a reality.
No hype, no B.S.
You’d have a hard time finding more dedicated advocates for your profit portfolio than the team here at TFN and Hot Stock Confidential.
Others investment research companies, you may have noticed, spend the majority of their time trying to get you to maximize your investment in them.
Finding our Hot Stock Confidential Members the next best opportunity for gains is our entire and sole focus.
Which brings me to the third stock in my report…
Company C: DNA-based therapy
This time the technology is deceptively simple to explain…
Company C has a patented core DNA delivery technology that allows them to directly address specific diseases.
This technology provides an immediate delivery of proteins created to stimulate an immune response or to suppress a malignant growth.
Their products cost less to manufacture.
The treatment is elemental and can be performed on outpatient basis.
There are no viral components in their treatments that could cause infection, immune responses or permanent changes to targeted cell’s genetic structure.
And again, Company C owns all the patents.
How important is this research?
This tiny company has collaboration agreements with the likes of Merck, Sanofi-Aventis Group, and Aqua Health Ltd., among others.
And one of its products is already in a Phase III clinical trial for patients with metastic melanoma.
That bodes well… very well… for their treatment.
There are also Phase I and II trials for other promising applications for this and other Company C products.
This company is truly on the verge of breaking out—and, unbelievably, its trading under $3 a share!
Get a copy of my Report and get started on the way to potential 422% gains—times 3!
And that’s just the beginning…
When you become a Member of Hot Stock Confidential, you’ll also receive immediate access to the following Special Reports:
 |
Jackpot Justice—Make Triple-Digit Gains On Superbug Litigation (A $99 value!)
This key to early life-saving diagnoses of a dreaded disease could bring BIG gains to early investors. |
|
The 3 Hottest Stem Cell Stocks Under $5 (A $129 value!)
Three stem cell stocks that are fast on the rise but are still going for cheap (at the moment). |
|
3 Recession-Busting Stocks You Need to Buy Now (A $129 value!)
Recommendations on how you could use current market conditions to profit from these 3 ready-to-breakout stocks. |
|
Profit From the Aging of America (A $129 value!)
3 stocks that are set to propel upward by sheer demographic pressure—no matter where the rest of the market is headed! |
That’s $486 worth of special reports—in addition to 3 Biotechs That Could Revolutionize Medicine (and make you RICH!).
But that’s not all…
Instant Alerts for Maximum Gains—each and every week
The key to successful investing in a market environment like this is timing: The instant an opportunity arises, we’ll notify you by special dedicated email.
To maximize your potential returns, it’s essential that you’re able to get into a recommendation within our advisable buying range—and get out as soon as we issue a sell alert.
That’s how Hot Stock Confidential Members had the opportunity to cash in on gains like 41.8% on Nymox Pharmaceutical, 38.4% on Alon USA, 26.7% on Synta Pharmaceuticals, 55% on Rex Energy, 44.2% on Bank of America and 83.2% on Altria 2008 Nov 22 17.00 Calls.
You can count on at least one breaking profit opportunity each week… on top of timely buy and sell alerts.
That’s right—I said “each week.” Not once a month like most research services, but at least one stock recommendation each and every week.
And we’ll provide you with concise updates on each and every open position in our Hot Stock Confidential tracking portfolio.
Plus we’ll give you access to all upcoming exclusive special reports—all via your email—to your cellphone, Blackberry, or any other digital information medium.
Hot Stock Confidential Members also receive…
- Full access to the Hot Stock Confidential Members only website with all of your reports, alerts, updates AND recommended portfolio.
- Directly to your email inbox, our TFN eNews free eletter every weekday. It’s full of useful information and market commentary.
But you need to move on this quickly… the pressure is already building under these 3 revolutionary biotech stocks currently going for a song!
Value for your hard-earned cash
You’ve seen how much a research service could set you back—$799, $999… or even $1,899 a year.
And frequently they provide just one or two recommendations a month.
As a Member of Hot Stock Confidential, you get a bare minimum of 1 DG (damn good) stock recommendation each week.
And you’ll get all of our Reports, Alerts and valuable research.
All for just $299 a year—if you accept this offer today!
Just $299…
That’s just about half of what you’d expect to pay for the 5 Research Reports alone—not to mention the investment recommendations you’ll receive at LEAST once a week.
How can this offer get any better?
Try us out for 90 days for just $79.
Or if you hate getting renewal notices, you can get an even better value…
BEST OFFER: You could have 90 days of Hot Stock Confidential for $69 with our auto-renew option.
You’ll get the hottest investment research around—for just $69 each quarter—locked in at that lowest of rates!—until you tell us to stop.
What Do You Have To Lose?
I would hate for you to miss out on this opportunity, but I know times are uncertain and you’re careful how you spend your money.
I know I need to earn your trust.
That’s why I insist you take a full 45 days to put Hot Stock Confidential to the test.
If you don’t like what you’re reading during that time, you can cancel for a full refund.
That translates into an absolute minimum of 6 trading recommendations… on top of those we make available to you in our confidential Special Reports.
Should you decide that Hot Stock Confidential is not for you during this period, all you have to do is let us know and we’ll reimburse every nickel of your Membership fee.
If you wish to cancel your Membership anytime after the 45 days, your refund will be prorated.
That’s my promise to you.
So please, act now before the window of opportunity for 422% gains closes for good on these 3 revolutionary biotech stocks.
You have absolutely nothing to lose.
Become a Member of Hot Stock Confidential and the TFN Profit Network today by selecting the button below.
Or if you’d prefer, call us directly at 1-877-465-1416.
Best regards,
Laura Cadden
Editor
Hot Stock Confidential
February 2009
P.S. Order today and you’ll receive access to the Special Reports 3 Biotechs That Could Revolutionize Medicine (and make you RICH!), The 3 Hottest Stem Cell Stocks Under $5, Jackpot Justice—Make Triple-Digit Gains On Superbug Litigation, 3 Recession-Busting Stocks You Need to Buy Now and Profit From the Aging of America. You get them all for just $299 for a full year or $79 for 90 days—or better yet, $69 for 90 days with our auto-renew option!
Next Article: Use options to leverage powerful gains
Be the first to leave a reply.
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down